Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2004

View Archived Issues

ORG-50081 enters phase II/III studies as nonhormonal menopausal therapy

Treatment commences in Dutch study of IMC-11F8 in solid tumors

Active Biotech's TTS-CD3 receives fast track designation for NSCLC

Approvable letter for hyponatremia drug YM-087

Fuji and JCR to enter into licensing agreement for JR-013

Diovan approved in Sweden to treat high-risk heart attack patients

Hexvix found fileable in 26 European countries

Priority review for Velcade for second-line multiple myeloma

APD-125 enters phase I study for insomnia

Controlled-release topiramate development stopped in obesity, type 2 diabetes

Iroxanadine shows promise for cardiovascular disease in mouse study

Prometheus Laboratories to market Entocort EC

Remicade sBLA for psoriatic arthritis accepted for filing

MVA-HPV-IL2 studied in new phase II trial for precancerous cervical lesions

FDA Advisory Committee positively endorses clofarabine for ALL

Intrinsa: potential risks outweigh sexual benefits

Soybean isoflavone metabolite inhibits bone loss in vivo

Conivaptan increases serum sodium levels in patients with hyponatremia

Tumor necrosis factor inhibitor may attenuate postmyocardial infarction ventricular remodeling

Hydrocortisone NO-releasing derivative shows greater antiinflammatory effects than parent compound

Orion claims new treatments for epilepsy using alpha2-adrenoceptor antagonists

New antimitotic agents described in patent literature

Taisho and Arena Pharmaceuticals jointly patent MCH receptor antagonists

Researchers at Meiji Seika isolate new compounds from Penicillium sp.

Janssen team presents new PCL-beta2 inhibitors

New factor Xa inhibitors in early development at Merck

PIN1 inhibitors described by Pfizer scientists

Syrrx researchers report DPP4 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.